Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Analysts at Wedbush decreased their FY2016 EPS estimates for Sarepta Therapeutics in a research note issued to investors on Monday. Wedbush analyst H. Behanna now expects that the brokerage will post earnings of ($5.31) per share for the year, down from their previous forecast of ($5.24). Wedbush has a “Outperform” rating and a $72.00 price objective on the stock. Wedbush also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.25) EPS, Q1 2017 earnings at ($1.15) EPS, Q2 2017 earnings at ($1.02) EPS, Q3 2017 earnings at ($0.99) EPS, Q4 2017 earnings at ($0.97) EPS, FY2017 earnings at ($4.14) EPS, FY2018 earnings at ($2.59) EPS and FY2019 earnings at ($0.93) EPS.

A number of other analysts have also weighed in on SRPT. Vetr raised Sarepta Therapeutics from a “sell” rating to a “hold” rating and set a $17.28 price objective on the stock in a research report on Monday, June 20th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, June 21st. Jefferies Group reaffirmed an “underperform” rating and set a $7.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, June 25th. William Blair reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a research report on Monday, June 27th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, June 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $58.44.

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT) opened at 54.19 on Wednesday. The stock’s market cap is $2.60 billion. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $63.73. The firm’s 50 day moving average price is $44.27 and its 200-day moving average price is $26.36.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter last year, the firm posted ($0.87) earnings per share.

In other news, SVP David T. Howton sold 7,000 shares of the stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $420,000.00. Following the completion of the sale, the senior vice president now owns 28,453 shares in the company, valued at $1,707,180. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the sale, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Eagle Asset Management Inc. increased its stake in shares of Sarepta Therapeutics by 67.5% in the third quarter. Eagle Asset Management Inc. now owns 593,455 shares of the company’s stock valued at $36,444,000 after buying an additional 239,165 shares during the period. BNP Paribas Arbitrage SA boosted its position in Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock valued at $217,000 after buying an additional 1,886 shares in the last quarter. Harbour Capital Advisors LLC purchased a new position in Sarepta Therapeutics during the second quarter valued at about $335,000. Schwab Charles Investment Management Inc. boosted its position in Sarepta Therapeutics by 1.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 153,816 shares of the company’s stock valued at $2,934,000 after buying an additional 2,766 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in Sarepta Therapeutics by 5.4% in the second quarter. Stifel Financial Corp now owns 23,076 shares of the company’s stock valued at $441,000 after buying an additional 1,178 shares in the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.